Amyloid pathology is defined as the initiating step of AD, which leads to subsequent tau deposition and neurodegeneration (Long and Holtzman, 2019); however, the well-established and validated biomarkers for brain amyloidosis detection, including cerebrospinal fluid (CSF) analysis and amyloid PET, are expensive, invasive, and difficult to implement on a large scale in clinical practice (Sperling et al., 2011, 2014; Dubois et al., 2014; Honig et al., 2018). This evidence concerns the gene MAPT and amyloidosis.